Ixarola 10mg Tablet contains Rivaroxaban, a direct oral anticoagulant that selectively inhibits Factor Xa, a key enzyme in the coagulation cascade responsible for thrombin generation and thrombus formation. It is indicated for the prevention and treatment of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for stroke prevention in patients with non-valvular atrial fibrillation. Ixarola 10mg offers a fixed-dose regimen without the need for routine coagulation monitoring, enhancing patient compliance and convenience. The drug demonstrates rapid onset of action with predictable pharmacokinetics and pharmacodynamics, allowing for consistent anticoagulant effects. It is contraindicated in patients with active pathological bleeding, severe hypersensitivity to Rivaroxaban, or significant hepatic impairment associated with coagulopathy. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Common adverse effects include bleeding complications, which require prompt medical attention. Ixarola should be used under medical supervision, with careful assessment of bleeding risk versus therapeutic benefit. It is essential to inform healthcare providers about concomitant medications to avoid potential drug interactions that may alter anticoagulant efficacy or increase bleeding risk. Overall, Ixarola 10mg Tablet is a valuable option for anticoagulation therapy in appropriate clinical settings.